MedTrace Logo

Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis

NCT01720238 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 621

Last updated 2015-07-28

No results posted yet for this study

Summary

Though newly reported HBV infection and HBsAg prevalence in China have greatly decreased, patients who had been chronically infected with HBV, especially those with liver cirrhosis cause great burden on public health care. In view of economic development level, drug availability and lack of independent health economics evidence, the investigators are still unable to give specific guidelines for HBV related compensated liver cirrhosis in China. Therefore, the investigators aim to investigate clinical effects and cost-effectiveness of two early anti-viral therapy strategies on HBV related compensated liver cirrhosis through this prospective, open-label, multicenter and nonrandomized study.

Conditions

Interventions

DRUG

Entecavir

0.5mg qd

DRUG

Lamivudine plus Adefovir Dipivoxil

Lamivudine:100mg qd Adefovir Dipivoxil:10mg qd

Sponsors & Collaborators

  • Peking University First Hospital

    collaborator OTHER

  • Peking University People's Hospital

    collaborator OTHER

  • Beijing YouAn Hospital

    collaborator OTHER

  • Beijing Tiantan Hospital

    collaborator OTHER

  • Beijing Ditan Hospital

    collaborator OTHER

  • Peking Union Medical College Hospital

    collaborator OTHER

  • Beijing 302 Hospital

    collaborator OTHER

  • Beijing Friendship Hospital

    lead OTHER

Principal Investigators

  • Dong Ji Jia, Doctor · Beijing Friendship Hospital

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2015-12-31
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01720238 on ClinicalTrials.gov